China NMPA has created several special fast-track registration channels for medical devices. To further expedite green channel pathways, China announced recently that approved innovative products can enjoy special pricing with higher premium enjoy reimbursement and exempt from China Volume based Purchasing (VBP). China is the second largest MedTech market and the only country with continuous double-digit growth. How can overseas companies benefit from accessing the China market faster with these special pathways? Innovation is one of the pre-market submission pathways with equal opportunity for both overseas and domestic manufacturers. In addition, there are other special pathways.
